Safety of immunotherapy side effects and restarting treatment
Part of Immune system & allergy clinical trials.
This study looks at patients who had side effects from cancer immunotherapy (checkpoint inhibitors). The goal is to understand those side effects and whether it is safe to restart immunotherapy after they resolve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a cancer diagnosis.
- You received treatment with a type of immunotherapy called a checkpoint inhibitor (such as drugs targeting PD-1, PD-L1, or CTLA-4).
- You had side effects from that immunotherapy that your doctor confirmed as immune-related.
- Your medical records have enough information for researchers to review your side effects and outcomes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study looks for markers in the blood that might predict side effects from immune checkpoint inhibitor therapy. By identifying these markers, doctors may better manage or prevent side effects for future patients.
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
This study collects blood, stool, and tissue samples from people who have had side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer). It aims to learn more about these side effects, so doctors can better manage them in the future.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Hear when a new Immune-Related Adverse Events trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.